OrthoPediatrics Corp. (NASDAQ: KIDS) expected to post quarterly sales of $ 25.06 million

Analysts expect OrthoPediatrics Corp. (NASDAQ: KIDS) Reports $ 25.06 Million in Revenue for Current Fiscal Quarter, According to Zacks investment research. Three analysts provided earnings estimates for OrthoPediatrics, with the highest sales estimate at $ 25.61 million and the lowest estimate at $ 24.76 million. OrthoPediatrics reported sales of $ 18.92 million in the same quarter last year, indicating a positive year-over-year growth rate of 32.5%. The company is expected to release its next earnings report on Wednesday, March 9.

According to Zacks, analysts expect OrthoPediatrics to report annual sales of $ 98.28 million for the current fiscal year, with estimates ranging from $ 97.99 million to $ 98.84 million. For the next fiscal year, analysts predict the company will report revenue of $ 121.03 million, with estimates ranging from $ 118.84 million to $ 125.20 million. Zacks Investment Research sales calculations are an average based on a survey of sales analysts who provide coverage for orthopediatrics.

OrthoPediatrics (NASDAQ: KIDS) last released its results on Wednesday, November 3. The company reported ($ 0.15) earnings per share for the quarter, exceeding Thomson Reuters consensus estimate ($ 0.28) by $ 0.13. The company reported sales of $ 25.08 million for the quarter. OrthoPediatrics had a negative net margin of 32.93% and a negative return on equity of 7.10%.

KIDS has been the subject of several research analyst reports. Truist Securities reduced its target price on OrthoPediatrics shares from $ 78.00 to $ 75 and established a “buy” rating for the company in a report released on Tuesday, December 21. Zacks investment research reduced shares of OrthoPediatrics from a “buy” note to a “keep” note in a research report released on Wednesday, October 6. Finally, BTIG Research lowered its price target for OrthoPediatrics shares from $ 75.00 to $ 68.00 and established a “buy” rating for the company in a research report published on Wednesday, December 22. One investment analyst rated the stock with a conservation rating and five gave the company a buy rating. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $ 75.14.

(A d)

Access our leading research platform which includes MarketBeat Daily Premium, portfolio monitoring tools, stock filters, research tools, real-time news feed, email and SMS alerts , the MarketBeat idea engine, exclusive brokerage rankings, extensive data export tools and more. Save 50% on your 2022 subscription. Only $ 1.00 for the first 30 days.

KIDS shares opened at $ 59.86 on Friday. OrthoPediatrics has a one-year minimum of $ 38.83 and a one-year maximum of $ 73.91. The company’s fifty-day average moving price is $ 61.78, and its two-hundred-day moving average price is $ 63.55. The company has a market cap of $ 1.18 billion, a P / E ratio of -38.13 and a beta of 0.77.

In other news, the main shareholder Jennifer N. Pritzker acquired 1,000 shares of the company in a transaction dated Thursday, December 9. The stock was purchased at an average cost of $ 60.42 per share, for a total transaction of $ 60,420.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 30.30% of the shares are held by insiders of the company.

Several hedge funds have recently increased or reduced their stakes in the company. Stifel Financial Corp increased its stake in OrthoPediatrics by 1.7% in the second quarter. Stifel Financial Corp now owns 10,740 shares of the company valued at $ 679,000 after purchasing an additional 180 shares in the last quarter. UBS Group AG increased its stake in OrthoPediatrics by 106.4% in the third quarter. UBS Group AG now owns 421 shares of the company valued at $ 28,000 after purchasing an additional 217 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in OrthoPediatrics by 2.9% in the second quarter. The Manufacturers Life Insurance Company now owns 7,993 shares of the company valued at $ 505,000 after purchasing an additional 227 shares in the last quarter. Tudor Investment Corp Et Al increased its stake in OrthoPediatrics by 2.2% in the third quarter. Tudor Investment Corp Et Al now owns 10,522 shares of the company valued at $ 689,000 after purchasing an additional 230 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in OrthoPediatrics by 8.3% in the second quarter. SG Americas Securities LLC now owns 3,088 shares of the company valued at $ 195,000 after purchasing an additional 236 shares in the last quarter. Institutional investors hold 76.34% of the shares of the company.

About orthopediatry

OrthoPediatrics Corp. is a medical device company dedicated to the design, development and marketing of anatomically appropriate implants and devices for children with orthopedic disorders. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM Nail, PediNailTM, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, RESPONSE Spine, Bandloc and Pediguard.

Recommended Story: How Do Investors Use RSI to Rate Stocks?

Get a free copy of the Zacks Orthopediatric Research Report (KIDS)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should You Invest $ 1,000 In Orthopediatrics Now?

Before you consider orthopediatry, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the larger market takes hold of… and OrthoPediatrics was not on the list.

While OrthoPediatrics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Previous Lawmakers face decisions over $ 1.5 billion in relief funds
Next Los Gatos Community Briefs for the week of January 7 - The Mercury News